Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 10/18/19
Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders GlobeNewsWire • 09/09/19
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in SeptemberGlobeNewsWire • 09/03/19